These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 14652793)

  • 41. Disability as an outcome in MS clinical trials.
    Ebers GC; Heigenhauser L; Daumer M; Lederer C; Noseworthy JH
    Neurology; 2008 Aug; 71(9):624-31. PubMed ID: 18480462
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In-vivo evidence for stable neuroaxonal damage in the brain of patients with benign multiple sclerosis.
    Benedetti B; Rovaris M; Rocca MA; Caputo D; Zaffaroni M; Capra R; Bertolotto A; Martinelli V; Comi G; Filippi M
    Mult Scler; 2009 Jul; 15(7):789-94. PubMed ID: 19465450
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Axonal injury in early multiple sclerosis is irreversible and independent of the short-term disease evolution.
    Rovaris M; Gambini A; Gallo A; Falini A; Ghezzi A; Benedetti B; Sormani MP; Martinelli V; Comi G; Filippi M
    Neurology; 2005 Nov; 65(10):1626-30. PubMed ID: 16301492
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MRI as an outcome in multiple sclerosis clinical trials.
    Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
    Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Compartmentalization of inflammation in the CNS: a major mechanism driving progressive multiple sclerosis.
    Meinl E; Krumbholz M; Derfuss T; Junker A; Hohlfeld R
    J Neurol Sci; 2008 Nov; 274(1-2):42-4. PubMed ID: 18715571
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Multiple sclerosis: a battle between destruction and repair.
    McQualter JL; Bernard CC
    J Neurochem; 2007 Jan; 100(2):295-306. PubMed ID: 17101032
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predicting and preventing the future: actively managing multiple sclerosis.
    Hutchinson M
    Pract Neurol; 2009 Jun; 9(3):133-43, discussion 144. PubMed ID: 19448055
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Changes at the nodal and perinodal axonal domains: a basis for multiple sclerosis pathology?
    Desmazières A; Sol-Foulon N; Lubetzki C
    Mult Scler; 2012 Feb; 18(2):133-7. PubMed ID: 22217583
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study.
    Agosta F; Absinta M; Sormani MP; Ghezzi A; Bertolotto A; Montanari E; Comi G; Filippi M
    Brain; 2007 Aug; 130(Pt 8):2211-9. PubMed ID: 17535835
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Insights into the molecular pathogenesis of progression in multiple sclerosis: potential implications for future therapies.
    Imitola J; Chitnis T; Khoury SJ
    Arch Neurol; 2006 Jan; 63(1):25-33. PubMed ID: 16401734
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosis.
    Rudick RA
    J Neuroimaging; 2004 Jul; 14(3 Suppl):54S-64S. PubMed ID: 15228760
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Axonal degeneration in the pathogenesis of multiple sclerosis].
    Mirowska D; Członkowska A
    Neurol Neurochir Pol; 2002; 36(4):777-89. PubMed ID: 12418141
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Axonal pathology in multiple sclerosis: relationship to neurologic disability.
    Trapp BD; Ransohoff R; Rudick R
    Curr Opin Neurol; 1999 Jun; 12(3):295-302. PubMed ID: 10499174
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Axonal injury in multiple sclerosis.
    Rammohan KW
    Curr Neurol Neurosci Rep; 2003 May; 3(3):231-7. PubMed ID: 12691628
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis.
    Dutta R; Trapp BD
    Prog Neurobiol; 2011 Jan; 93(1):1-12. PubMed ID: 20946934
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis.
    Peterson LK; Fujinami RS
    J Neuroimmunol; 2007 Mar; 184(1-2):37-44. PubMed ID: 17196667
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Future options for therapies to limit damage and enhance recovery.
    Compston A
    Semin Neurol; 1998; 18(3):405-14. PubMed ID: 9817543
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Axonal degeneration in the pathogenesis of multiple sclerosis.
    Silber E; Sharief MK
    J Neurol Sci; 1999 Nov; 170(1):11-8. PubMed ID: 10540030
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neurodegeneration and neuroprotection in multiple sclerosis.
    Stangel M
    Curr Pharm Des; 2012; 18(29):4471-4. PubMed ID: 22612743
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serotonergic neuronal atrophy with synaptic inactivation, not axonal degeneration, are the main hallmarks of multiple sclerosis.
    Sandyk R
    Int J Neurosci; 1998 Jul; 95(1-2):133-40. PubMed ID: 9845023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.